Loading…

Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers

An increase in amoxicillin-induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris RCPVs) and better describe this rare adverse drug reaction. For...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2018-03, Vol.62 (3)
Main Authors: Vodovar, Dominique, Thomas, Laure, Mongardon, Nicolas, Lepeule, Raphaël, Lebrun-Vignes, Bénédicte, Biour, Michel, Netzer, Florence, Haouache, Hakim, Le Beller, Christine, Dhonneur, Gilles
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3
cites cdi_FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3
container_end_page
container_issue 3
container_start_page
container_title Antimicrobial agents and chemotherapy
container_volume 62
creator Vodovar, Dominique
Thomas, Laure
Mongardon, Nicolas
Lepeule, Raphaël
Lebrun-Vignes, Bénédicte
Biour, Michel
Netzer, Florence
Haouache, Hakim
Le Beller, Christine
Dhonneur, Gilles
description An increase in amoxicillin-induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris RCPVs) and better describe this rare adverse drug reaction. Forty-five AICN cases were identified between 1985 and 2016. All cases, except one, were reported since 2010. Amoxicillin (AMX) was administered intravenously (65 [interquartile range {IQR}, 43 to 110] mg/kg of body weight/day) in all patients, either for treating infection ( = 15) or as surgical prophylaxis ( = 30). Delay between AMX administration and AICN onset was 1 (IQR, 1 to 3) day; 30, 4, and 11 patients developed KDIGO stage 1, 2, and 3 acute kidney injury, respectively. Delay between AICN onset and kidney function recovery was 4 (IQR, 2 to 6) days. Precipitating factors were identified in only one-third of cases. Twelve patients required intensive care unit admission, and 8 needed renal replacement therapy. Neither chronic kidney disease nor death was observed. We confirmed the recent and dramatic increase of AICN in the Paris RCPVs since 2010. The absence of precipitating factors in the majority of cases and the onset of AICN in apparent routine indications, such as surgical prophylaxis, are alarming and justify a high vigilance from all AMX prescribers.
doi_str_mv 10.1128/AAC.01630-17
format article
fullrecord <record><control><sourceid>hal_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5826165</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_03907629v1</sourcerecordid><originalsourceid>FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3</originalsourceid><addsrcrecordid>eNp1kUFr3DAQhUVoaLZpbzkXXQtxKsmWbF8Kxuk2C0sSaHIWY0mOFWxpkewl--_j7bZpUuhhEDN67xukh9AZJReUsuJrVdUXhIqUJDQ_QgtKyiIRvBTv0IIQIZKsINkJ-hDjI5l7XpL36ISVbDbkxQI9XQYYYLQKr5wKBqLBvsXV4J-ssn1vXbJyelJG4zrs4gg9vjabLvgNjN0OL_3kNLYOA65958OIf46T3u0Ry2Cc6vBtB2EA5bf2wfbglMG1caMJ8SM6bqGP5tPv8xTdL7_f1VfJ-ubHqq7WCWScjUkjiJ6rBNW0jFBDmwYoNCTTrYDc8BwYb4QhRGe5KlKhmOaaClCcK6aYSU_RtwN3MzWD0WreHqCXm2AHCDvpwcq3N8528sFvJS-YoILPgC8HQPeP7apay_2MpCXJBSu3dNaeH7Qq-BiDaV8MlMh9WnJOS_5KS9L8LxriwOSjn4Kbv-J_2s-v3_EC_hNl-gxTFJ72</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>Vodovar, Dominique ; Thomas, Laure ; Mongardon, Nicolas ; Lepeule, Raphaël ; Lebrun-Vignes, Bénédicte ; Biour, Michel ; Netzer, Florence ; Haouache, Hakim ; Le Beller, Christine ; Dhonneur, Gilles</creator><creatorcontrib>Vodovar, Dominique ; Thomas, Laure ; Mongardon, Nicolas ; Lepeule, Raphaël ; Lebrun-Vignes, Bénédicte ; Biour, Michel ; Netzer, Florence ; Haouache, Hakim ; Le Beller, Christine ; Dhonneur, Gilles</creatorcontrib><description>An increase in amoxicillin-induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris RCPVs) and better describe this rare adverse drug reaction. Forty-five AICN cases were identified between 1985 and 2016. All cases, except one, were reported since 2010. Amoxicillin (AMX) was administered intravenously (65 [interquartile range {IQR}, 43 to 110] mg/kg of body weight/day) in all patients, either for treating infection ( = 15) or as surgical prophylaxis ( = 30). Delay between AMX administration and AICN onset was 1 (IQR, 1 to 3) day; 30, 4, and 11 patients developed KDIGO stage 1, 2, and 3 acute kidney injury, respectively. Delay between AICN onset and kidney function recovery was 4 (IQR, 2 to 6) days. Precipitating factors were identified in only one-third of cases. Twelve patients required intensive care unit admission, and 8 needed renal replacement therapy. Neither chronic kidney disease nor death was observed. We confirmed the recent and dramatic increase of AICN in the Paris RCPVs since 2010. The absence of precipitating factors in the majority of cases and the onset of AICN in apparent routine indications, such as surgical prophylaxis, are alarming and justify a high vigilance from all AMX prescribers.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.01630-17</identifier><identifier>PMID: 29263078</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Acute Kidney Injury ; Adult ; Aged ; Aged, 80 and over ; Amoxicillin ; Cohort Studies ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Life Sciences ; Male ; Middle Aged ; Pharmacology ; Pharmacovigilance ; Retrospective Studies ; Toxicology</subject><ispartof>Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)</ispartof><rights>Copyright © 2018 American Society for Microbiology.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3</citedby><cites>FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3</cites><orcidid>0000-0003-2756-4052</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.01630-17$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.01630-17$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3175,27901,27902,52726,52727,52728,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29263078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03907629$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Vodovar, Dominique</creatorcontrib><creatorcontrib>Thomas, Laure</creatorcontrib><creatorcontrib>Mongardon, Nicolas</creatorcontrib><creatorcontrib>Lepeule, Raphaël</creatorcontrib><creatorcontrib>Lebrun-Vignes, Bénédicte</creatorcontrib><creatorcontrib>Biour, Michel</creatorcontrib><creatorcontrib>Netzer, Florence</creatorcontrib><creatorcontrib>Haouache, Hakim</creatorcontrib><creatorcontrib>Le Beller, Christine</creatorcontrib><creatorcontrib>Dhonneur, Gilles</creatorcontrib><title>Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>An increase in amoxicillin-induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris RCPVs) and better describe this rare adverse drug reaction. Forty-five AICN cases were identified between 1985 and 2016. All cases, except one, were reported since 2010. Amoxicillin (AMX) was administered intravenously (65 [interquartile range {IQR}, 43 to 110] mg/kg of body weight/day) in all patients, either for treating infection ( = 15) or as surgical prophylaxis ( = 30). Delay between AMX administration and AICN onset was 1 (IQR, 1 to 3) day; 30, 4, and 11 patients developed KDIGO stage 1, 2, and 3 acute kidney injury, respectively. Delay between AICN onset and kidney function recovery was 4 (IQR, 2 to 6) days. Precipitating factors were identified in only one-third of cases. Twelve patients required intensive care unit admission, and 8 needed renal replacement therapy. Neither chronic kidney disease nor death was observed. We confirmed the recent and dramatic increase of AICN in the Paris RCPVs since 2010. The absence of precipitating factors in the majority of cases and the onset of AICN in apparent routine indications, such as surgical prophylaxis, are alarming and justify a high vigilance from all AMX prescribers.</description><subject>Acute Kidney Injury</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amoxicillin</subject><subject>Cohort Studies</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pharmacology</subject><subject>Pharmacovigilance</subject><subject>Retrospective Studies</subject><subject>Toxicology</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kUFr3DAQhUVoaLZpbzkXXQtxKsmWbF8Kxuk2C0sSaHIWY0mOFWxpkewl--_j7bZpUuhhEDN67xukh9AZJReUsuJrVdUXhIqUJDQ_QgtKyiIRvBTv0IIQIZKsINkJ-hDjI5l7XpL36ISVbDbkxQI9XQYYYLQKr5wKBqLBvsXV4J-ssn1vXbJyelJG4zrs4gg9vjabLvgNjN0OL_3kNLYOA65958OIf46T3u0Ry2Cc6vBtB2EA5bf2wfbglMG1caMJ8SM6bqGP5tPv8xTdL7_f1VfJ-ubHqq7WCWScjUkjiJ6rBNW0jFBDmwYoNCTTrYDc8BwYb4QhRGe5KlKhmOaaClCcK6aYSU_RtwN3MzWD0WreHqCXm2AHCDvpwcq3N8528sFvJS-YoILPgC8HQPeP7apay_2MpCXJBSu3dNaeH7Qq-BiDaV8MlMh9WnJOS_5KS9L8LxriwOSjn4Kbv-J_2s-v3_EC_hNl-gxTFJ72</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Vodovar, Dominique</creator><creator>Thomas, Laure</creator><creator>Mongardon, Nicolas</creator><creator>Lepeule, Raphaël</creator><creator>Lebrun-Vignes, Bénédicte</creator><creator>Biour, Michel</creator><creator>Netzer, Florence</creator><creator>Haouache, Hakim</creator><creator>Le Beller, Christine</creator><creator>Dhonneur, Gilles</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2756-4052</orcidid></search><sort><creationdate>20180301</creationdate><title>Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers</title><author>Vodovar, Dominique ; Thomas, Laure ; Mongardon, Nicolas ; Lepeule, Raphaël ; Lebrun-Vignes, Bénédicte ; Biour, Michel ; Netzer, Florence ; Haouache, Hakim ; Le Beller, Christine ; Dhonneur, Gilles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acute Kidney Injury</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amoxicillin</topic><topic>Cohort Studies</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pharmacology</topic><topic>Pharmacovigilance</topic><topic>Retrospective Studies</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vodovar, Dominique</creatorcontrib><creatorcontrib>Thomas, Laure</creatorcontrib><creatorcontrib>Mongardon, Nicolas</creatorcontrib><creatorcontrib>Lepeule, Raphaël</creatorcontrib><creatorcontrib>Lebrun-Vignes, Bénédicte</creatorcontrib><creatorcontrib>Biour, Michel</creatorcontrib><creatorcontrib>Netzer, Florence</creatorcontrib><creatorcontrib>Haouache, Hakim</creatorcontrib><creatorcontrib>Le Beller, Christine</creatorcontrib><creatorcontrib>Dhonneur, Gilles</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vodovar, Dominique</au><au>Thomas, Laure</au><au>Mongardon, Nicolas</au><au>Lepeule, Raphaël</au><au>Lebrun-Vignes, Bénédicte</au><au>Biour, Michel</au><au>Netzer, Florence</au><au>Haouache, Hakim</au><au>Le Beller, Christine</au><au>Dhonneur, Gilles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>62</volume><issue>3</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>An increase in amoxicillin-induced crystal nephropathy (AICN) incidence has been recently suggested. The aims of this study were to investigate the trend of AICN incidence through Paris' regional centers of pharmacovigilance (Paris RCPVs) and better describe this rare adverse drug reaction. Forty-five AICN cases were identified between 1985 and 2016. All cases, except one, were reported since 2010. Amoxicillin (AMX) was administered intravenously (65 [interquartile range {IQR}, 43 to 110] mg/kg of body weight/day) in all patients, either for treating infection ( = 15) or as surgical prophylaxis ( = 30). Delay between AMX administration and AICN onset was 1 (IQR, 1 to 3) day; 30, 4, and 11 patients developed KDIGO stage 1, 2, and 3 acute kidney injury, respectively. Delay between AICN onset and kidney function recovery was 4 (IQR, 2 to 6) days. Precipitating factors were identified in only one-third of cases. Twelve patients required intensive care unit admission, and 8 needed renal replacement therapy. Neither chronic kidney disease nor death was observed. We confirmed the recent and dramatic increase of AICN in the Paris RCPVs since 2010. The absence of precipitating factors in the majority of cases and the onset of AICN in apparent routine indications, such as surgical prophylaxis, are alarming and justify a high vigilance from all AMX prescribers.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>29263078</pmid><doi>10.1128/AAC.01630-17</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2756-4052</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2018-03, Vol.62 (3)
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5826165
source American Society for Microbiology Journals; PubMed Central
subjects Acute Kidney Injury
Adult
Aged
Aged, 80 and over
Amoxicillin
Cohort Studies
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Life Sciences
Male
Middle Aged
Pharmacology
Pharmacovigilance
Retrospective Studies
Toxicology
title Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A36%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dramatic%20Increase%20of%20Amoxicillin-Induced%20Crystal%20Nephropathy%20Found%20in%20a%20Cohort%20Study%20of%20French%20Pharmacovigilance%20Centers&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Vodovar,%20Dominique&rft.date=2018-03-01&rft.volume=62&rft.issue=3&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.01630-17&rft_dat=%3Chal_pubme%3Eoai_HAL_hal_03907629v1%3C/hal_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a452t-b60db609acbf201e1bba1ab04df6a7e57a25b6e00d47c836c2d5d16ac55c2c2e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29263078&rfr_iscdi=true